Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.)(Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.)) - 药物靶点：CD19_在研适应症：血液肿瘤，可见病灶，B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名

Anti-CD19 chimeric antigen receptor T cell therapy - Yake Biotechnology

靶点

CD19

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、T淋巴细胞替代物

治疗领域

肿瘤血液及淋巴系统疾病其他疾病+ [1]

在研适应症

血液肿瘤可见病灶B细胞淋巴瘤+ [1]

非在研适应症

B细胞白血病CD19 表达恶性肿瘤残留肿瘤

原研机构

上海雅科生物科技有限公司

在研机构

上海雅科生物科技有限公司

浙江大学

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

6

项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的临床试验

NCT05239676 / Recruiting早期临床1期IIT

Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

开始日期2022-02-28

申办/合作机构

浙江大学

[+1]

NCT04790747 / Recruiting临床1/2期IIT

Clinical Trial for the Safety and Efficacy of Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions

开始日期2021-03-01

申办/合作机构

浙江大学

[+1]

NCT04661020 / Recruiting临床2期IIT

Clinical Trial for the Safety and Efficacy of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

A Study of CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma.

开始日期2020-12-03

申办/合作机构

浙江大学

[+1]

100 项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

14

项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的文献（医药）

2023-12-01·Molecular Therapy - Methods & Clinical Development

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

Article

作者: Wong, Steven ; Völkl, Simon ; Patel, Darshil ; Müller, Fabian ; Volkov, Jenell ; Vorndran, Zachary ; Mackensen, Andreas ; Basu, Samik ; Schett, Georg ; Nunez, Daniel ; Aigner, Michael

Chimeric antigen receptor (CAR) T cells targeting CD19⁺ B cells have demonstrated efficacy in refractory systemic lupus erythematosus (SLE). Although initial clinical data suggest that anti-CD19 CAR T cell therapy is well tolerated and highly effective, the immunologic consequences of CAR T cell therapy in SLE patients remain unclear. We profiled serum in six refractory SLE patients prior to and 3 months following CAR T cell infusion. Three months post T cell infusion, the inflammatory cytokines IL-6 and TNFα decreased in patient sera. This was accompanied by elevations in serum IL-7 and BAFF. Furthermore, SLE-associated antibodies dropped profoundly in five of six patients. Last, consistent with other reports of CD19 CAR T therapy in B cell malignancies, we were able to show marginal impact of anti-CD19 CART therapy on pre-existing humoral immune responses in SLE patients. Together, these results provide insights into the mechanisms of efficacy of anti-CD19 CAR T cell therapy in SLE.

2023-11-01·Seminars in Hematology

Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options

Article

作者: Fabbri, N ; Mussetti, A ; Sureda, A

In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy. However, 30%-40% relapse after initial response to first-line therapy and, out of them, 20%-50% are refractory or experience early relapse. The second-line therapy algorithm for DLBCL has recently evolved, thanks to the recent approval of new therapeutic agents or their combinations. The new guidelines suggest a stratification of relapsed/refractory (R/R) DLBCL based on the time to relapse. For transplant-eligible patients, autologous stem cell transplant remains the preferred option when the patient relapses after 12 months from diagnosis, while anti-CD19 CART-cell therapy is the current preferred choice for high-risk DLBCL, defined as primary refractory or relapse ≤12 months. For transplant-ineligible or CAR T-cell therapy-ineligible patients, the therapeutic arsenal historically lacked effective options. However, new therapeutic options, including polatuzumab vedotin combined with bendamustine-rituximab and tafasitamab with lenalidomide, have been recently approved, and novel agents such as loncastuximab tesirine, selinexor, anti-CD19 CAR T-cell therapy, and bispecific antibodies have shown promising efficacy and manageable safety in this setting offering new hope to patients in this challenging scenario.

2023-07-01·British Journal of Haematology

Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

Article

作者: Avni, B. ; Stepensky, P. ; Kfir-Erenfeld, S. ; Asherie, N. ; Assayag, M. ; Goldschmidt, N. ; Gatt, M. E. ; Dubnikov Sharon, T. ; Lebel, E. ; Grisariu, S.

SummaryBackgroundChimeric antigen receptor (CAR) T cells targeted to the CD19 B‐cell antigen form an approved treatment for patients with relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). However, since this therapy is administered after multiple lines of treatment and exposure to lymphotoxic agents, there is an urgent need to optimize this modality of treatment.MethodsTo circumvent the difficulties of harvesting adequate and optimal T cells from DLBCL patients and improve CART therapy, we suggest an earlier lymphopheresis (i.e. at first relapse, before salvage treatment). We conducted a prospective study and evaluated the potential benefit of an earlier lymphopheresis (early group, n = 22) on the clinical outcome of CD19‐CART infused DLBCL patients, in comparison with standard lymphopheresis (i.e. at second relapse and beyond; standard group, n = 23).ResultsAn increased percentage of naïve T cells and increased in vitro T‐cell functionality were observed in the early group. Additionally, these cells exhibit a lower exhaustion profile than T cells collected in the standard group.ConclusionWhile improved T‐cell phenotype and function in the lymphopheresis product did not translate into significantly improved clinical outcomes, a trend towards better overall survival (OS) and progression‐free survival (PFS) was observed. Early lymphopheresis maximizes the potential of salvage therapies, without compromising CAR T‐cell quality.

100 项与 Anti-CD19 CART cell therapy(Shanghai YaKe Biotechnology Co., Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CD19 表达恶性肿瘤	临床3期	中国	上海雅科生物科技有限公司	2018-07-15
残留肿瘤	临床3期	中国	上海雅科生物科技有限公司	2018-07-15
血液肿瘤	临床2期	中国	浙江大学	2021-03-01
血液肿瘤	临床2期	中国	上海雅科生物科技有限公司	2021-03-01
可见病灶	临床2期	中国	浙江大学	2021-03-01
可见病灶	临床2期	中国	上海雅科生物科技有限公司	2021-03-01
B细胞淋巴瘤	临床1期	中国	浙江大学	2020-08-23
难治性 B 细胞急性淋巴细胞白血病	临床1期	中国	浙江大学	2020-08-23
难治性 B 细胞急性淋巴细胞白血病	临床1期	中国	上海雅科生物科技有限公司	2020-08-23
B细胞白血病	药物发现	中国	上海雅科生物科技有限公司	2018-07-15